14 Arunachal Pradesh districts eligible for malaria-free certification

Itanagar: 14 out of the 25 districts in Arunachal Pradesh are now eligible for malaria-free certification, according to Dr KT Mulung, state program officer for the National Center for Vector Borne Disease Control (NCVBDC).   

According to the PTI report, Mulung was speaking at the inauguration of the three-day state review meeting on vector-borne diseases organised by NCVBDC at Naharlagun near here.  

The meeting focused on evaluating the state’s efforts towards malaria elimination and reviewing the progress in combating vector-borne diseases.  

Additional Senior Regional Director of the Regional Offices of Health and Family Welfare, Shillong and Guwahati, Dr Juliana Lyngwa praised the remarkable reduction in malaria cases in the state.

Also Read:WHO Recommends new Malaria Vaccine for children which is cost-effective and efficient

Lyngwa attributed the achievement to the dedication of health officials and field staff.  

She also stressed the importance of proper documentation to ensure smooth progress towards receiving malaria elimination certification.  

State Family Welfare Director Dr Amping Perme underlined the department’s commitment to achieving a malaria-free Arunachal Pradesh in the near future, news agency PTI reported.  

National Health Mission (NHM) Mission Director Marge Sora assured of proper allocation of funds for vector-borne disease control programmes.  

The meeting, which will conclude on October 17, will review the strategies and develop actionable plans to accelerate the progress towards a malaria-free Arunachal Pradesh.  

Medical Dialogues team had earlier reported that several hospitals in Delhi are seeing an increased footfall of dengue patients, doctors said, even as the city’s civic body has not released reports on vector-borne diseases for the last several weeks.  

Sources at the Ram Manohar Lohia (RML) Hospital here said on Tuesday that a 38-year-old woman suffering from dengue died on September 17 at the Centre-run medical facility.  

Powered by WPeMatico

Gilead withdraws bladder cancer drug Trodelvy in US

Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients with a type of bladder cancer after consultation with the U.S. health regulator.

The U.S. Food and Drug Administration had granted accelerated approval to Trodelvy, an antibody-drug conjugate, for metastatic urothelial cancer in 2021, while its continued approval was dependent on results of a confirmatory trial.

Also Read: Gilead Sciences inks pacts with Dr Reddy’s Labs, Emcure, Hetero and 3 others for HIV drug Lenacapavir

The drug, however, failed to improve survival for patients with advanced bladder cancer in the trial.

Shares of the drugmaker fell 1.3% to $86.25 in premarket trading

The decision does not affect approval for Trodelvy for other patients within or outside of the U.S., the company said.

Powered by WPeMatico

Merck eyes more acquisitions for life science after USD 600M Mirus Bio deal

Gdansk: German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for $600 million, it said ahead of its Capital Markets day on Thursday.
“Our guiding principle is and always has been, the right target, at the right time, for the right price,” CEO Belen Garijo said in a statement.
“For larger future transactions, Merck is focusing on the Life Science business sector,” the firm added.
Shares in the group were up 6.06% at 0727 GMT. ODDO BHF analyst Oliver Metzger attributed the move chiefly to gains in German pharma peer Sartorius, whose shares jumped 13% on Thursday after it said it expects an improved second half.
Merck narrowed expectations for its Life Science business, aiming for annual organic sales growth in a 7-9% range from a previously anticipated 7-10%.
It also said it will intensify the in-licensing of drug candidates in its Healthcare division.
The Hesse-based company changed its outlook for its Healthcare business to “slight growth”, compared to a previously expected mid-single-digit percentage range, due to “recently announced pipeline setbacks”, the statement said.
Merck has reported a string of setbacks in the development of cancer and multiple sclerosis drugs in recent years.
The company however raised the mid-term outlook for its electronics division to a 5-9% range from a previous 3-6%, benefiting from high demand for chips for AI applications.

Powered by WPeMatico

CVS Health CEO steps down amid financial challenges

New Delhi: CVS Health CEO Karen Lynch has stepped down with company shares down 19% this year and the national drugstore chain struggling.
Lynch will be replaced by David Joyner, who will attempt to steer the health care giant through a worsening environment of rising medical costs.
CVS cut its financial expectations for the third time in August with all major pharmacy chains attempting to navigate a drastically changed landscape, facing competition online and elsewhere.
Joyner, who will also join the company’s board, most recently served as executive vice president of CVS Health, and president of CVS Caremark. He led the pharmacy services business, which provides solutions to employers, health plans and government entities and serves approximately 90 million members through Caremark, CVS Specialty, and other areas. Joyner has 37 years of health care and pharmacy benefit management experience.
CVS Health also announced on Friday that Chairman Roger Farah will now be executive chairman.
“We believe David and his deep understanding of our integrated business can help us more directly address the challenges our industry faces, more rapidly advance the operational improvements our company requires, and fully realize the value we can uniquely create,” Farah said in a statement.
The Woonsocket, Rhode Island company’s preliminary forecast is for third-quarter adjusted earnings of $1.05 to $1.10 per share, citing higher-than-expected medical cost trends. Analysts polled by FactSet predict earnings of $1.69 per share.
Back in August CVS Health changed the leadership of its health insurance business as it continued to deal with escalating costs. At the time, the company named Lynch to lead its insurance segment, replacing Executive Vice President Brian Kane, who is left the company about a year after arriving.
Rising claims from the company’s Medicare Advantage coverage have hurt CVS Health for much of this year and contributed to repeated trimmings of its outlook for 2024. Medicare Advantage plans are privately run versions of the federal government’s coverage program mainly for people age 65 and older.
CVS Health also said in August that it has been hurt by a drop in quality ratings for those plans and pressure from Medicaid coverage it manages in several states.
CVS Health’s stock is down nearly 13% before the market open on Friday.

Powered by WPeMatico

Kezar to terminate mid-stage trial for Lupus treatment

Bengaluru: Kezar Life Sciences said on Thursday it would terminate its mid-stage trial studying its experimental drug in patients with active lupus nephritis and focus on developing the drug for a rare chronic disorder called autoimmune hepatitis.
Earlier this month, the U.S. Food and Drug Administration placed a clinical hold on the trial of the drug, zetomipzomib, studying it in patients with active lupus nephritis, which causes inflammation and damage in the kidneys due to a form of immune-related condition called lupus.
The regulator’s decision came after the company paused the study in September to review safety data following the deaths of four patients.
An independent study committee had recommended a pause on the trial after it found that three of the fatalities showed a common pattern of symptoms and the deaths happened close to the time of dosing, while a non-fatal adverse event also showed a similar proximity to the dosing time.
Kezar said it would continue its mid-stage trial in patients with autoimmune hepatitis, a disease in which the immune system attacks the liver and causes inflammation and tissue damage, without modification after the review of an independent committee.
Till date, no serious adverse events have been observed in the trial, Kezar said.

Separately, Kezar said its board has rejected Concentra Biosciences’ proposal to buy the company’s outstanding shares for $1.10 apiece in cash.

Powered by WPeMatico

Krishna Eye Centre launches new Contoura Vision Laser machine

Mumbai: Krishna Eye Centre, a key facility of the ASG Group of Hospitals, has proudly introduced its new Contoura Vision Laser machine, enhancing its ability to provide comprehensive eye care.
Founding directors Dr Sonia and Dr Gul Nankani shared insights about the new facility, which spans 7,000 sq. ft. and is equipped with advanced technology to treat a wide range of eye conditions. KEC offers specialized treatments across various subspecialties of ophthalmology, including Cataract, Cornea, Glaucoma, Pediatric, Retina, and Squint, supported by a team of renowned ophthalmologists. The centre also features an in-house optical showroom and pharmacy, ensuring that all eye-related needs can be met under one roof.
According to an ANI report, Dr Gul Nankani emphasized the vision of Krishna Eye Centre, stating, “Our goal is to serve all classes of patients with the latest technology, embodying our motto: ‘Seeing is Believing.’ Since our inception, we have catered to over 100,000 patients from India and abroad, establishing a reputation for advanced cataract surgeries that significantly reduce dependence on glasses.”
The newly acquired Contoura Vision Laser machine represents a leap forward in LASIK technology, offering superior visual quality and spectacle freedom. Unlike traditional LASIK procedures that merely correct refractive errors, Contoura Vision enhances the visual experience by mapping 22,000 unique points on the cornea, akin to fingerprints. This technology creates a 3D image, allowing the laser to polish the cornea selectively, resulting in improved vision quality.
The procedure is swift, taking only 10 minutes to complete, with a recovery time of just 24-48 hours.
In addition to advanced surgical options, Krishna Eye Centre stands out for its comprehensive management of Computer Vision Syndrome (CVS), a growing concern as digital media usage increases. With over 750 million internet users in India, 70 per cent of whom experience CVS symptoms such as headache and eye strain, KEC offers unique evaluation and treatment methods, news agency ANI reported.
Patients presenting external symptoms like redness and irritation are assessed using the LipiView and LipiFlow machines, which provide an in-depth analysis of the tear film’s layers. This advanced technology enables effective treatment of clogged glands, promoting the secretion of high-quality tears.
For those experiencing internal symptoms such as headache and eye strain, KEC employs a patented software program called Bynocs. This engaging 10-day program offers targeted exercises that can be performed at home or in the office, ensuring lasting relief from symptoms.
With its innovative approach to eye care, Krishna Eye Centre has successfully treated thousands of patients suffering from CVS and aims to continue leading the way in comprehensive eye health solutions. 

Powered by WPeMatico

Apollo Hospital absolved from Allegations of Inflating Medical Bills

Mumbai: The District Consumer Disputes Redressal Commission (DCDRC), Mumbai Suburban Additional recently dismissed a complaint against Apollo Spectra Hospital in Chembur for allegedly charging an inflated bill for a minor foot surgery.

Ruling in favour of the hospital, the District Consumer Court concluded that the charges were justified and also pointed out that before the surgery, the complainant had been fully informed about the surgery expenses.

The history of the case goes back to 2018 when the patient approached the treating consultant general and laparoscopic surgeon at Apollo Spectra Hospital for examination for a small lump on the middle toe of left foot. Based on the treating doctor’s advice, blood test, X-ray, ECG etc were conducted and consequently, the doctor advised for a minor operation.

As per the complaint, the doctor performed a 10-15 minute operation but later the patient was shocked to find that the final bill of the hospital was of Rs 1,01,500 for such a small/nominal operation. Additionally, deposit amount, medicines etc. were allegedly taken from the complainant for examination/tests from the hospital.

Protesting against this, the patient asked the hospital administration to charge an appropriate amount. However, the hospital administration allegedly told the complainant that the hospital had a package for each operation and patients were billed accordingly. When he objected to this, he was given a discount of Rs 15,225 and the final bill was calculated at Rs 86,275. 

Later, the patient filled a consumer complaint for cheating by charging exorbitant bills, providing defective service and following unfair business practice and requested the hospital to charge an appropriate amount and return the remaining amount, pay Rs 50,000 as compensation and Rs 10,000 as compensation for financial fraud committed by the hospital.

On the other hand, the hospital denied all the allegations and submitted that the complainant never objected to the diagnosis. As per the hospital, the complainant contacted the insurance company’s representative available at the hospital voluntarily and submitted the forms and related documents to complete the Medi-claim process with Apollo Munich Health Insurance.

Thereafter, the operation was conducted on the left middle toe and after the post-operative examination, the complainant was discharged. The hospital billed Rs 1,01,500 to the complainant and later gave a discount of Rs 15,225 and thereafter the total amount was billed by the insurance company. The hospital claimed that the patient made false complaints regarding the increased bill for the treatment.

It was further submitted that even though the complainant received the best diagnosis and medical treatment, he voluntarily and knowingly consented to the treatment at the front desk, he brought up wrong allegations to get more discount on his total bill

While considering the matter, the consumer court noted that if none of the expenses incurred in the said mediclaim were eligible then the insurance company would definitely have denied it. However, that was not the case. 

Further, the Commission noted that the complainant gave his consent for the surgery on 08.11.2018 in a letter stating that “I take full responsibility of settling all the bills before leaving the Hospital”. Also in the said consent letter, the complainant was asked to explain in a language that the complainant understood and it was clear that the complainant’s signature was there. 

“It is clear that the complainant’s hospital expenses were immediately paid by his insurance company. Therefore, the complainant cannot file a complaint in that regard now,” opined the consumer court.

“Frontline hospitals are reputed hospitals and according to their prevailing standard of practice, how and how much they charge is decided. If the said cost is not affordable to the complainant then alternative hospital is available to him at that time. However, instead of going to any other hospital, the complainant underwent treatment / operation at the above hospital. Hence, it is clear from the above discussion that the appellant has not resorted to unfair business practice by charging exorbitant bills,” it further noted.

Therefore, taking note of all these aspects, the Commission dismissed the consumer complaint against Apollo Spectra Hospital.

To view the order, click on the link below:

https://medicaldialogues.in/pdf_upload/apollo-257396.pdf

Also Read: Hospital slapped Rs 6.54 Crore fine for Tampering with Medical Reports, Inflating Bills under PMJAY Scheme

Powered by WPeMatico

KNRUHS to close Mop-Up Phase Web Options for MBBS Admissions Under Competent Authority Quota, Details

Telangana- Kaloji Narayan Rao University of Health Sciences (KNRUHS) has released a notification regarding the exercising of web options for the mop-up phase of counselling for MBBS admission under the competent authority quota for the academic year 2024-25.

Through the notification, KNRUHS has notified all the candidates regarding the conduct of Mop Up phase of web-based counseling for vacant seats after the 2nd phase of Counselling and newly sanctioned seats of Nova Institute of Medical Sciences and Research Center, Hayathnagar under Competent Authority Quota (C.Q) for MBBS course for 2024-25 in Government, Private Medical Colleges in the State of Telangana.

KNRUHS has recently released the provisional final merit list of UG Medical Admissions on the KNRUHS official website. Therefore, candidates whose names are notified in the provisional final merit list are eligible to exercise web – options online.

As per the notification, all the eligible candidates whose names are displayed in the Provisional final merit list can exercise web options for admission into MBBS seats from today i.e. 19th October 2024 from 06.00 A .M. to 20 October 2024 till 06.00 P.M. through the KNRUHS official website.

UNIVERSITY FEE

Allotted Candidates have to pay the University fee of Rs. 12,000/- for the MBBS Course through a payment Gateway by using the Online payment method such as Debit Card, Credit Card and Internet Banking and download the allotment letter. However, candidates who have paid University fees in the previous phases need not pay again. Also, the University fee once paid should not be refunded under any circumstances.

TUITION FEES

Tuition fees are to be paid at respective Medical colleges. Below are the detailed tuition fees-

S.NO

COLLEGE

FEE (Rs)

1

Government Medical Colleges.

10,000/- per year.

2

Private Medical Colleges and ESIC.

60,000/- per year.

Meanwhile, the original certificates submitted at the time of admissions should not be returned to the candidate, unless the candidate discontinues the course before Mop Up phase of counselling or before the last date for free exit to be notified by the University

To view the notification, click the link below

Powered by WPeMatico

Amputation of Newborn’s Leg- Gynaecologist, Paediatric surgeon slapped Rs 50 Lakh Compensation for negligence

New Delhi: The National Consumer Disputes Redressal Commission (NCDRC) recently directed two doctors belonging to two private hospitals in Patna to pay Rs 50 lakh compensation to a woman for medical negligence leading to the amputation of her newborn son’s leg.

After being treated for chest infection and breathing problems, initially, the child’s condition stabilized. However, soon afterwards, the complainant noted discolouration of the child’s left foot. Ultimately, the newborn was transferred to Sir Ganga Ram Hospital, where the leg had to be amputated.

The history of the case goes back to 2007 when the complainant had delivered a baby boy in the hospital of Dr. Sinha, a Gynaecologist. However, the baby was suffering from chest infection and breathing problems and required consultation with a child specialist. Therefore, advice was sought from Dr. Kumar, a Paediatrician surgeon and after that the baby was admitted to Dr. Kumar’s hospital (Kids Care) in a Neonatal ICU on the ventilator. 

After stabilization, the baby was put on intravenous (IV) feed on the 3rd day, and on the 6th day, while breastfeeding the child, the complainant noticed that the baby’s left foot was blue. After this was brought to Dr. Kumar’s notice, he conducted a Doppler test after much persuasion. Consequently, the child was taken to Sir Ganga Ram Hospital, where despite treatment for thrombus in descending aorta and treatment for plasminogen activor, the left foot below the knee had to be amputated as it had become gangrenous. 

Thereafter, filing a consumer complaint before the State Commission, the mother alleged that the two doctors had failed to provide adequate, proper and timely care to the new born baby and prayed for Rs 50 lakh compensation along with interest and litigation costs.

Earlier, while considering the matter, the State Commission had dismissed the complaint noting that the woman submitted no medical expert opinion to show that the treatment provided by the doctors was wrong or that the medicines given to the patient increased the infection.

Challenging the State Commission’s order, the complainant approached the NCDRC bench and contended that based on the record, neither the Paediatrician nor Neonatologist was present at the Hospital of Dr Sinha at the time of birth and therefore, the baby was required to be moved to the Nursing Home of Dr. Kumar. 

Further, the appellant contended that due to heavy doses of medication, inappropriate treatment and inordinate delay in treatment by Dr. Kumar and medical negligence of the treating doctors, the baby’s left leg had to be amputated. 

It was also argued that Dr. Sinha himself had admitted that at the time of birth, no qualified Neonatologist or Pediatrician were present and since the newborn started having breathing problems within a few minutes of birth, Dr. Kumar had to be called.

The complainant also alleged that despite observing the blue colouration of the left foot on the 6th day, Dr. Kumar failed to take the appropriate steps immediately and conducted the Doppler test only on the 8th Day whereafter the report was sent to Sir Ganga Ram Hospital, New Delhi and agreed to discharge the child after much persuasion. The complainant alleged that Dr. Kumar submission that the blue colouration was noticed on the 8th day of admission was incorrect and contrary to the Treatment-Cum-Progress Chart which was the record of the hospital itself. 

Apart from this, the complainant also contended that the conclusion that the child had developed thromboembolism was also incorrect since it was evident from the record that on the 8th day at around 10 PM, Peripheral Cyanosis was recorded in the treatment chart.

On the other hand, the treating doctors argued that as per the Discharge Summary issued by Sir Ganga Ram Hospital, New Delhi, after being treated for respiratory distress and being on ventilator for three days and being on IV fluids and antibiotics, the patient (child) had started to accept feeds by the 6th day and therefore, the line of treatment was correct. As per the doctors, the parents reported of the discolouration of the left leg only on the 8th day. They also stressed that no doctor at Sir Ganga Ram Hospital found any medical negligence on their part and the same was evident from the discharge summary.

While considering the matter, the top consumer court perused the Treatment cum Progress Chart of the Kids Care Hospital and noted that on the 6th day, the chart noted at 10 PM “Pink Peripheral Cyanosis” and thereafter on 21.12.2007 at 4:30 PM it was recorded as “Change of colour of status of left leg” and “Opinion of Pediatric Surgeon and Cardiovascular Surgeon should be taken” followed by a remark at 10 PM stating “Left foot pale, cold. Surgical Opinion.”

The Commission noted that the patient was discharged on 21.07.2007 and as per the Discharge Slip dated 21.02.2007 issued by the “Kids care” hospital, the baby was admitted on 11.02.2007 and was given treatment including IV fluid, injections, and symptomatic with ventilation for three days. Respiratory distress had settled by 6th day and baby had started breastfeeding for two days. investigation done included Colour Doppler of Left Limb which showed ‘No pulsation of dp and post lipid artery’. The diagnosis was ‘RDS with avascular nacrosis of right foot fingers’. Advice on discharge was ‘Refer to higher center for needful’.

Meanwhile, the Discharge Summary of Sir Ganga Ram Hospital mentioned that at the time of admission, “Left foot was gangrenous with crepitus palpable. Line of demarcation present 2 inches above the left ankle joint. Rt lower limb was also cyanosed.” A CT angiography was done which revealed a large occlusive thrombus in the descending aorta and extending in both lower limbs. Baby was given a trial of tissue plasminogen activator, which failed to show any response. The coagulation profile was normal and sepsis work up revealed candida paracilosis from blood and urine cultures which was treated with amphotericin B.

Regarding the issue of expert medical opinion, the Commission noted that the case was not a complicated matter of transplant of an organ or surgery. It was essentially whether the newborn child of the complainant who was under care of Dr. Kumar in his Nursing Home, was detected to be suffering from Peripheral Cyanosis in time and whether the doctor, after diagnosis either extend the treatment as per prescribed medical protocol or refer him to a higher centre for treatment.

“The moot issue is whether a duty of care was owed by the Respondent No. 2 (pediatric surgeon) as a medical professional and whether this duty was breached resulting in harm to the patient as a result of which he suffered damages,” observed the Commission.

Opining that the paediatric surgeon failed to provide duty of care owed to the patient, the Commission observed,

“From the facts of the case, it is patently manifest that the newborn child/patient was in the care of the Respondents and therefore a duty of care was owed by them to him. By delaying the recording of the fact of Peripheral Cyanosis and the conduct of the Doppler Test including consultation with another expert, Dr HK Verma, the duty of care was breached by the Respondent No. 2. This breach caused harm to and led to the damage suffered by the patient. Therefore, the case is eminently covered under the principle of res ipsa loquitur. The State Commission has clearly fallen in error in holding that there was no expert opinion produced and, on this ground, dismissed the complaint.”

“It is also evident that the damage/harm occurred due to negligence on part of Respondent No. 2 in failing to act promptly and taking steps when Peripheral Cyanosis was detected since the patient was in his exclusive care at that point of time. The contention of Respondent No. 2 that the patient was found to have had an thrombosis in aorta in the abdomen for which thrombotitis was conducted at Sir Ganga Ram Hospital is essentially to contend that the cause of amputation was not Peripheral Cyanosis which was detected while the patient was in his care. It is, however, clear from the records of Sir Gangaram Hospital that the patient was admitted on 22.07.2007 with a gangrenous with crepitus palpable left foot and right lower limb also cyanosed although haemodynamically stable. Thus, it is apparent that the damage/harm (amputation of the left leg) would not have occurred without negligence of Respondent No. 2. It is also evident that Respondent Nos. 1 (gynecologist) and 2 had exclusive control over the circumstances that led to the damage that was suffered and that there was no contributory negligence on part of the patient/attendants,” it further noted.

Therefore, the Commission opined that the State Commission acted erroneously in requiring an expert opinion when the matter was not a complex one warranting expert evidence but was rather one of adjudicating whether the conduct of the Doppler Test and reference to a higher centre for further treatment was done timely as per the duty of care imposed upon Dr. Kumar, the paediatrician surgeon.

“From the medical records of treatment in the hospital of Respondent No. 2 it is apparent that the patient’s discolouration of the left leg had indeed come on the daily Treatment-cum-Progress Chart. A Dopplers Test was done which revealed “arterial blockage due to thrombosis in aorta of abdomen and low level of protein in respiratory distress syndrome” as per the Respondents themselves,” noted the NCDRC bench.

Referring to the doctors’ contention that the diagnosis of Sir Ganga Ram Hospital was also that the patient required thrombolysis with tissue plasminogen and due to the failure of this treatment the left leg was required to be amputated below the knee, the Commission observed that from the records it was clear that at the time of admission to Sir Ganga Ram Hospital, the patient’s “Left foot was gangrenous with crepitus palpable. Line of demarcation present 2 inches above the left ankle joint. Rt lower limb was also cyanosed.”

Holding both the doctors guilty of medical negligence, the Commission observed,

“The contention of the Respondents that the patient was diagnosed correctly and on the correct line of treatment while under the care of Respondent No. 2 therefore cannot be accepted. There is no reference to any sepsis or gangrene in the Discharge Slip dated 21.02.2007 issued by Kids Care hospital. It is also evident that the Doppler Test was done after 10 th day of the patient’s left foot condition having been noted in the Treatment-CumProgress Chart. From the record, it is manifest that the instant case is covered by the principle of res ipsa loquitur. Accordingly, we hold Respondents 1 and 2 jointly and severally liable for medical negligence and deficiency in service in the treatment of the patient (newborn child of Appellant). For the aforesaid reasons, the First Appeal is liable to succeed and is accordingly upheld and allowed.”

Accordingly, the Apex Consumer Court directed the doctors to pay Rs 50 lakh as compensation and Rs 50,000 as legal cost to the complainant.

To view the order, click on the link below:

https://medicaldialogues.in/pdf_upload/patna-doctors-rs-50-l-257329.pdf

Also Read: Thumb Amputation due to gangrene- Expert Evidence Vital in Determining Medical Negligence, says Court

Powered by WPeMatico

Non-inclusion of disability, transgender rights laws in new CBME curriculum, Centre seeks NMC response

After the Madras High Court’s concerns regarding the way of addressing the gender identity issues in the new Competency-Based Medical Education 2024 curriculum, now the Union Ministry of Social Justice and Empowerment has sought a response from the National Medical Commission (NMC) over the non-inclusion of disability and transgender rights laws in the new MBBS curriculum.
Writing to the Secretary of NMC, the Department of Social Justice and Empowerment mentioned in an Office Memorandum, “The undersigned (NMC) is directed to the representation made to Hon’ble Minister of Social Justice & Empowerment by Shri Siddhartha Singh, Doctors with Disabilities and Air Cmde (Dr.) Sanjay Sharma (Retd.), CEO and MD Association for Transgender Health vide letter dated 13.09.2024… and to say that you are requested to examine this matter on priority and submit your reply within 15 days.”

For more information, click on the link below:

Powered by WPeMatico